Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Biofrontera ( (BFRI) ) just unveiled an announcement.
On June 30, 2025, Biofrontera Inc. finalized an agreement with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a royalty payment structure and grants Biofrontera AG a 10% equity stake in Biofrontera Inc. through Series D Convertible Preferred Stock. Additionally, a private placement of Series C Preferred Stock was initiated on June 27, 2025, to fund the acquisition, with proceeds expected to reach $11 million. This move is expected to enhance Biofrontera Inc.’s market presence in the U.S. and streamline its operations by consolidating rights to its key products.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s stock score reflects mixed financial performance with ongoing profitability challenges, balanced by strategic restructuring efforts. Technical indicators show neutrality, while valuation and Nasdaq compliance issues highlight potential risks.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. operates in the pharmaceutical industry, focusing on dermatological products. The company is known for its products Ameluz® and RhodoLED®, which are primarily marketed in the United States.
Average Trading Volume: 163,001
Technical Sentiment Signal: Sell
Current Market Cap: $5.68M
Find detailed analytics on BFRI stock on TipRanks’ Stock Analysis page.